CYCN - CIK 0001755237
The table below shows Cyclerion Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.31M | -$4.33M | -$21.25M | -$40.61M | -$36.52M | -$72.49M |
| Capital expenditure | - | - | - | $0.00 | $7.00K | $1.52M |
| Investing cash flow | - | $0.00 | $10.40M | $0.00 | $1.46M | $18.00K |
| Dividends paid | - | - | - | - | - | - |
Cyclerion Therapeutics, Inc. reported operating cash flow of -$3.31M for fiscal year 2025. That is up 23.5% from -$4.33M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$97.50M (FY 2018) to -$3.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $3.32M | $0.00 | $5.02M | $29.00K | $30.79M | $28.09M |